A landmark study led by Mount Sinai researchers estimates Phelan-McDermid syndrome (PMS) affects approximately 1 in 7,300 individuals—far more than prior estimates. PMS is caused by deletions or mutations in the SHANK3 gene, which plays a critical role in neurological development. The condition often co-occurs with autism spectrum disorder (ASD), and SHANK3 disruptions may account for up to 1% of ASD cases.
The study analyzed genetic data from nearly 180,000 people with autism, combining insights from major testing labs and research programs. Despite its prevalence, many cases go undiagnosed due to barriers like inadequate testing coverage or insurance limitations. Researchers emphasize that broader genetic screening could uncover thousands of hidden cases, enabling earlier interventions.
"We recommend that every child with autism undergo genetic testing, because knowledge is power." — Joseph D. Buxbaum, PhD
Why This Matters
Understanding the true prevalence of PMS is vital for advancing targeted therapies. Clinical trials are already exploring treatments tailored to SHANK3-related pathways, offering hope for improved quality of life. Early diagnosis can also connect families with specialized support networks and resources.
The findings underscore systemic gaps in genetic testing accessibility, particularly for neurodivergent individuals. Advocates stress that equitable access to testing could reduce diagnostic delays and empower families with actionable information about their loved ones’ health.
What You Can Do
If you or a loved one has autism or unexplained developmental challenges, ask healthcare providers about comprehensive genetic testing. Tests like chromosomal microarray analysis (CMA) or whole-exome sequencing can identify SHANK3 mutations. Organizations like CureSHANK offer guidance and advocacy for families navigating PMS diagnoses.
Support research by participating in studies like the SPARK autism project, which aims to improve genetic understanding of neurodevelopmental conditions. Sharing your experiences can help shape future therapies and policies for underrepresented genetic disorders.
